IP Library › Granted Patent US 11,547,683
Granted Patent B2
US 11,547,683 · App. 17/305,009 · Granted Jan 10, 2023

Therapeutic compounds, formulations, and uses thereof

Inventors: Imran Alibhai (Sugar Land, TX); Sofia De Achaval (Missouri City, TX); Beverly C. Langevin (Stewartsville, NJ); Tian Zhou (Philadelphia, PA)
Assignee: Tvardi Therapeutics, Inc.
A61K31/18A61K9/0053A61K9/4825A61K9/4858A61K9/4866A61K9/4875
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,547,683
App. No.
17/305,009
Granted
Jan 10, 2023
Kind
B2
Abstract

Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.

Claims (25)

1. A pharmaceutical composition comprising:

a. at least 50 mg of a compound of Formula (I):

b. a glyceride emulsifier present in the composition in a weight ratio of compound of Formula (I) to emulsifier of about 1:1 to about 1:2;

c. a solubilizer present in the composition in a weight ratio of compound of Formula (I) to solubilizer of about 1:2 to about 1:4, wherein the solubilizer is polyoxyl castor oil;

d. a polyethylene glycol (PEG) present in the composition in a weight ratio of compound of Formula (I) to polyethylene glycol of about 1:3 to about 1:5;

e. a surfactant present in the composition in a weight ratio of compound of Formula (I) to surfactant of about 1:1 to about 1:2, wherein the surfactant is polysorbate; and

f. an antioxidant present in the composition in a weight ratio of compound of Formula (I) to surfactant of about 15:1 to about 25:1.

2. The pharmaceutical composition of claim 1 , wherein the polyoxyl castor oil is PEG-40 hydrogenated castor oil.

3. The pharmaceutical composition of claim 1 , wherein the PEG has an average molecular weight of about 200 to about 1000 Da.

4. The pharmaceutical composition of claim 1 , wherein the polysorbate is polysorbate 20.

5. The pharmaceutical composition of claim 1 , wherein the antioxidant is citric acid.

6. The pharmaceutical composition of claim 1 , wherein at least 50 mg of the glyceride emulsifier, at least 100 mg of the solubilizer, at least 150 mg PEG, at least 50 mg of surfactant, and at least 2 mg of the antioxidant are present in the pharmaceutical composition.

7. An oral dosage form comprising the pharmaceutical composition of claim 1 contained within a capsule.

8. A method of treating cancer in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

9. The method of claim 8 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, prostate cancer, cervical cancer, brain cancer, pancreatic cancer, myelodysplastic syndrome, leukemia, lymphoma, neuroblastoma, kidney cancer, or metastatic melanoma.

10. The method of claim 8 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, leukemia, or pancreatic cancer.

11. A method of treating fibrosis in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

12. The method of claim 11 , wherein the fibrosis is associated with pulmonary fibrosis, intestine fibrosis, pancreatic fibrosis, joint fibrosis, liver fibrosis, retroperitoneal fibrosis, myelofibrosis, dermal fibrosis, non-alcoholic fatty liver disease, steatohepatitis, or systemic sclerosis.

13. The method of claim 11 , wherein the fibrosis is associated with pulmonary fibrosis, non-alcoholic fatty liver disease, steatohepatitis, or systemic sclerosis.

14. A method of treating chronic inflammation in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

15. A method of treating chemotherapy-induced peripheral neuropathy in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

16. A method of treating diabetic neuropathy in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

17. A method of treating familial amyloid polyneuropathy in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

18. A method of treating cachexia in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

19. A method of treating anaphylaxis in an individual in need thereof, the method comprising administering to the individual the oral dosage form of claim 7 .

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Oct 7, 2025
From: TVARDI THERAPEUTICS, INC.; CT CONVERGENCE MERGER SUB, INC.
To: TVARDI OPERATING COMPANY, INC.
Reel/Frame 072492/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2021
From: ALIBHAI, IMRAN; DE ACHAVAL, SOFIA
To: TVARDI THERAPEUTICS, INC.
Reel/Frame 056708/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2021
From: LANGEVIN, BEVERLY C.; ZHOU, TIAN
To: ASCENDIA PHARMACEUTICALS LLC
Reel/Frame 056708/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2021
From: ASCENDIA PHARMACEUTICALS LLC
To: TVARDI THERAPEUTICS, INC.
Reel/Frame 056708/0886 →
Continuity (4)
Continuation 17203639 · Mar 16, 2021
Continuation PCTUS2021014642 · Jan 22, 2021
Provisional Application 62965738 · Jan 24, 2020
Related Publication 20210322347A1 · Oct 21, 2021
Cited By (1)
US 12,617,810